OR WAIT null SECS
Kenny Walter is an editor with HCPLive. Prior to joining MJH Life Sciences in 2019, he worked as a digital reporter covering nanotechnology, life sciences, material science and more with R&D Magazine. He graduated with a degree in journalism from Temple University in 2008 and began his career as a local reporter for a chain of weekly newspapers based on the Jersey shore. When not working, he enjoys going to the beach and enjoying the shore in the summer and watching North Carolina Tar Heel basketball in the winter.
Patients treated with ustekinumab are not at an increased risk of malignancies.
Ustekinumab is moving toward the top of the class of biologics for the treatment of inflammatory bowel disease (IBD) , not only in terms of efficacy, but also safety.
Now several years into research on the treatment, safety concerns might be few and far between.
In new data presented during 2022 Digestive Disease Week Annual Meeting in San Diego, investigators found little evidence of malignancies following ustekinumab treatment for patients with ulcerative colitis, as well as psoriatic arthritis.
In the study, the investigators followed 6710 patients treated with ustekinumab for up to 5 years, involving 13,807 years of follow-up.
The incidence rate of patients with at least 1 malignancies per 100 patient-years for all malignancies was 1.00 (95% CI, 0.84-1.118), compared to 0.73 for the placebo group.
In an interview with, HCPLive®, Millie D. Long, MD, MPH, FACG, University of North Carolina, explained how the study just adds to a growing list of reasons ustekinumab is safe and effective for patients with IBD.
Long also spoke in favor of the treatment as an option for patients with either ulcerative colitis or Crohn’s disease as a lot of biologics favor 1 disease over the other.